Vertex Announces CASGEVY™ Reimbursement Agreement for the Treatment of Transfusion-Dependent Beta Thalassemia in EnglandBusiness Wire • 08/07/24
Prediction: 2 Stocks That Will Be Worth More Than Johnson & Johnson 10 Years From NowThe Motley Fool • 08/03/24
Vertex Pharmaceuticals Lifts Annual Guidance, Positive Growth For Its Cystic Fibrosis Franchise And Pain Management PipelineBenzinga • 08/02/24
Should You Invest in Vertex (VRTX) Based on Bullish Wall Street Views?Zacks Investment Research • 08/02/24
Vertex Pharma: Driving Growth Through Suzetrigine And Next-Gen Cystic Fibrosis TreatmentSeeking Alpha • 08/02/24
Should Investors Worry About Vertex Pharmaceuticals $3.6 Billion Q2 Loss? Not Even for a Second.The Motley Fool • 08/02/24
Vertex Pharmaceuticals (VRTX) Reports Q2 Loss, Misses Revenue EstimatesZacks Investment Research • 08/01/24
Vertex Slumps As Guidance Hike — Featuring The Gene-Editing Launch — Fails To Erase LossesInvestors Business Daily • 08/01/24
Vertex Pharma raises annual revenue forecast on strong demand for its cystic fibrosis treatmentsReuters • 08/01/24
Vertex Announces FDA Acceptance of New Drug Application for Suzetrigine for the Treatment of Moderate-to-Severe Acute PainBusiness Wire • 07/30/24
Curious about Vertex (VRTX) Q2 Performance? Explore Wall Street Estimates for Key MetricsZacks Investment Research • 07/29/24